Skip to main content

Project C2: Olena Denysenko, doctoral researcher (PhD)

Broadly neutralizing antibodies that bind to viral fusion might block the protein fusion process in order to prevent infection, but they are difficult to produce. As a substitute, antibody-derived peptides may be used for this purpose. Peptides are easy to develop both in terms of time and technology and are cost-effective, which makes them good candidates for drug design. In our project, we aim to design novel peptides with enhanced antibody properties by analyzing complexes between antibodies and SARS CoV-2 fusion protein structure.

In addition, these novel peptides may be used for creating a bispecific ligand(s) that binds to the spike protein of SARS CoV-2 by covalently linking two peptide ligands that recognize neighboring sites of the antigen.